Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.56 EUR | +3.06% | +1.90% | -17.26% |
01:37pm | ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial | MT |
06-07 | Geron shares surge after U.S. FDA approves blood disorder drug | RE |
Sales 2024 * | 46.09B 42.82B 63.42B | Sales 2025 * | 46.06B 42.79B 63.38B | Capitalization | 84.08B 78.13B 116B |
---|---|---|---|---|---|
Net income 2024 * | -5.41B -5.03B -7.45B | Net income 2025 * | 10.22B 9.5B 14.06B | EV / Sales 2024 * | 2.67 x |
Net Debt 2024 * | 39.03B 36.27B 53.72B | Net Debt 2025 * | 31.68B 29.43B 43.59B | EV / Sales 2025 * | 2.51 x |
P/E ratio 2024 * |
-15.8
x | P/E ratio 2025 * |
7.85
x | Employees | 34,100 |
Yield 2024 * |
5.8% | Yield 2025 * |
6.09% | Free-Float | 69.27% |
Latest transcript on Bristol-Myers Squibb Company
1 day | +3.06% | ||
1 week | +1.90% | ||
Current month | +1.90% | ||
1 month | -5.73% | ||
3 months | -21.65% | ||
6 months | -18.06% | ||
Current year | -17.26% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
Date | Price | Change |
---|---|---|
24-06-06 | 38.39 | +1.91% |
24-06-10 | 38.78 | +1.00% |
24-06-07 | 38.39 | +1.91% |
24-06-06 | 37.67 | -0.50% |
24-06-05 | 37.86 | -1.46% |
End-of-day quote Borsa Italiana, June 06, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.39% | 765B | |
-6.13% | 354B | |
+20.61% | 331B | |
+10.00% | 299B | |
+18.87% | 248B | |
-1.96% | 219B | |
+11.11% | 216B | |
+5.80% | 164B | |
-2.50% | 162B |
- Stock Market
- Equities
- BMY Stock
- 4BMY Stock